InsidersTradesSigma
Explore the detailed record of transactions filed by Shah Sujal, Chairman & CEO. Officer active across 1 companies, notably CymaBay Therapeutics, Inc.. Aggregated, 1 disclosures have been logged. Total volume traded: €94k. The latest transaction was filed on 6 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
1 of 1 declaration
Sujal Shah is the Chairman & CEO of CymaBay Therapeutics, Inc. He is responsible for the strategic direction of the company and the management of its operations. Sujal brings expertise in business development and innovation to support the company's growth.